(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
04 November 2021 (04.11.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/222065 A8

(51) International Patent Classification:
C12N 15/113 (2010.01) *C07H 21/00* (2006.01)
A61K 31/713 (2006.01) *A61P 25/28* (2006.01)

(21) International Application Number:
PCT/US2021/029081

(22) International Filing Date:
26 April 2021 (26.04.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/015,867 27 April 2020 (27.04.2020) US

(71) Applicant: **ALNYLAM PHARMACEUTICALS, INC.** [US/US]; 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA 02142 (US).

(72) Inventors; and
(71) Applicants: **BOSTWICK, Bret, Lee** [US/US]; 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA 02142 (US). **PENG, Haiyan** [CN/US]; 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA 02142 (US). **MCININCH, James, D.** [US/US]; 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA 02142 (US). **CASTORENO, Adam** [US/US]; 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA 02142 (US). **SCHLEGEL, Mark, K.** [US/US]; 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA 02142 (US).

(74) Agent: **ZACHARAKIS, Maria Laccotripe** et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:
09 December 2021 (09.12.2021)

(15) Information about Correction:
see Notice of 09 December 2021 (09.12.2021)

(54) Title: APOLIPOPROTEIN E (APOE) IRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF

(57) Abstract: The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting an APOE gene, as well as methods of inhibiting expression of an APOE gene and methods of treating subjects having an APOE-associated neurodegenerative disease or disorder, e.g., Alzheimer's disease and Parkinson's disease, using such dsRNAi agents and compositions.

WO 2021/222065 A8